Reviewing Corbus Pharmaceuticals (NASDAQ:CRBP) & TAIWAN LIPOSOME/S (TLC)

Corbus Pharmaceuticals (NASDAQ:CRBP) and TAIWAN LIPOSOME/S (NASDAQ:TLC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.

Profitability

This table compares Corbus Pharmaceuticals and TAIWAN LIPOSOME/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Corbus Pharmaceuticals -1,154.52% -116.34% -87.13%
TAIWAN LIPOSOME/S -1,442.64% -167.30% -74.44%

Institutional and Insider Ownership

40.2% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 2.2% of TAIWAN LIPOSOME/S shares are held by institutional investors. 12.6% of Corbus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Corbus Pharmaceuticals and TAIWAN LIPOSOME/S’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Corbus Pharmaceuticals $4.82 million 94.28 -$55.67 million ($0.98) -7.19
TAIWAN LIPOSOME/S $2.04 million 93.39 -$29.93 million ($0.47) -12.72

TAIWAN LIPOSOME/S has lower revenue, but higher earnings than Corbus Pharmaceuticals. TAIWAN LIPOSOME/S is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Corbus Pharmaceuticals and TAIWAN LIPOSOME/S, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corbus Pharmaceuticals 0 0 7 0 3.00
TAIWAN LIPOSOME/S 0 0 4 0 3.00

Corbus Pharmaceuticals currently has a consensus price target of $25.86, suggesting a potential upside of 266.77%. TAIWAN LIPOSOME/S has a consensus price target of $10.33, suggesting a potential upside of 72.80%. Given Corbus Pharmaceuticals’ higher possible upside, equities research analysts clearly believe Corbus Pharmaceuticals is more favorable than TAIWAN LIPOSOME/S.

Summary

Corbus Pharmaceuticals beats TAIWAN LIPOSOME/S on 9 of the 12 factors compared between the two stocks.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug to resolve chronic inflammation and fibrotic processes in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases. The company was founded in 2009 and is based in Norwood, Massachusetts.

About TAIWAN LIPOSOME/S

Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site. The company provides various product candidates that target various areas of unmet medical need in pain management, ophthalmology, and oncology. Its lead product candidate is TLC599, is an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP) that is in Phase II clinical trials for knee osteoarthritis pain. The company's product candidates also comprises TLC399, BioSeizer formulation of DSP intended as an intravitreal injection for the treatment of macular edema due to retinal vein occlusion; TLC590, a non-opioid anesthetic for post-surgical pain management; and TLC178, an API to treat rhabdomyosarcoma. Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei City, Taiwan with offices in Hsinchu, Hong Kong, Leiden, Melbourne, Shanghai, South San Francisco, and Tokyo.

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.